Copyright
©The Author(s) 2018.
World J Transplant. Aug 9, 2018; 8(4): 84-96
Published online Aug 9, 2018. doi: 10.5500/wjt.v8.i4.84
Published online Aug 9, 2018. doi: 10.5500/wjt.v8.i4.84
Table 6 European Association for the Study of the Liver Recommendations for treating hepatitis C virus in patients with reduced or absent renal function
Hemodialysis patients, particularly those who are suitable candidates for renal transplantation, should be considered for antiviral therapy (B1) |
Hemodialysis patients should receive an IFN-free, if possible ribavirin-free regimen, for 12 wk in patients without cirrhosis, for 24 wk in patients with cirrhosis (B1) |
Simeprevir, daclatasvir, and the combination of ritonavir-boosted paritaprevir, ombitasvir and dasabuvir are cleared by hepatic metabolism and can be used in patients with severe renal disease (A1) |
Sofosbuvir should not be administered to patients with an eGFR < 30 mL/min per 1.73 m2 or with end-stage renal disease until more data is available (B2) |
- Citation: Salvadori M, Tsalouchos A. Hepatitis C and renal transplantation in era of new antiviral agents. World J Transplant 2018; 8(4): 84-96
- URL: https://www.wjgnet.com/2220-3230/full/v8/i4/84.htm
- DOI: https://dx.doi.org/10.5500/wjt.v8.i4.84